

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM453118

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
CMP Pharma, Inc.		12/01/2017	Corporation: NORTH CAROLINA
CMP Acquisition Company LLC		12/01/2017	Limited Liability Company: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	First Tennessee Bank National Association
<b>Street Address:</b>	211 Franklin Road
<b>Internal Address:</b>	Suite 300
<b>City:</b>	Brentwood
<b>State/Country:</b>	TENNESSEE
<b>Postal Code:</b>	37027
<b>Entity Type:</b>	national association: UNITED STATES

## PROPERTY NUMBERS Total: 10

Property Type	Number	Word Mark
<b>Serial Number:</b>	86418628	CAROSPIR
<b>Registration Number:</b>	4031253	CAROLINA MEDICAL PRODUCTS CO.
<b>Registration Number:</b>	1526453	CMP
<b>Registration Number:</b>	4028443	DERMACLOUD
<b>Registration Number:</b>	1288620	SPS
<b>Registration Number:</b>	3358469	CAROLINA MEDICAL PRODUCTS CO.
<b>Registration Number:</b>	1600274	ABSORBASE
<b>Registration Number:</b>	1377857	ORACIT
<b>Registration Number:</b>	4517401	CMP
<b>Registration Number:</b>	4046667	TRIANEX

## CORRESPONDENCE DATA

Fax Number: 6152482954

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 615-742-7944

Email: trademarks@bassberry.com

TRADEMARK

**Correspondent Name:** Martha B. Allard  
**Address Line 1:** 150 3rd Avenue South  
**Address Line 2:** Suite 2800  
**Address Line 4:** Nashville, TENNESSEE 37201

**ATTORNEY DOCKET NUMBER:** 105528-179

**NAME OF SUBMITTER:** Martha B. Allard

**SIGNATURE:** /Martha B. Allard/

**DATE SIGNED:** 12/04/2017

**Total Attachments: 9**

source=security agreement#page1.tif  
source=security agreement#page2.tif  
source=security agreement#page3.tif  
source=security agreement#page4.tif  
source=security agreement#page5.tif  
source=security agreement#page6.tif  
source=security agreement#page7.tif  
source=security agreement#page8.tif  
source=security agreement#page9.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

**THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT**, dated as of December 1, 2017 (as amended, supplemented or otherwise modified from time to time, the “Intellectual Property Security Agreement”), is made by the undersigned (the “Grantors”) in favor of First Tennessee Bank National Association, as administrative agent for itself and the Lenders (in such capacity, the “Administrative Agent”) under the Credit Agreement.

### RECITALS

WHEREAS, pursuant to that certain Credit Agreement of even date herewith by and among CMP PHARMA, INC., a North Carolina corporation (the “Borrower”), CMP ACQUISITION COMPANY LLC, a Delaware limited liability company (“Parent Guarantor”), the banks and other financial institutions or entities (the “Lenders”) from time to time parties thereto and Administrative Agent (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) and pursuant to that certain Guarantee and Collateral Agreement of even date herewith by and among Borrower, Parent Guarantor, and Administrative Agent (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”); capitalized terms not otherwise defined herein and not otherwise noted parenthetically as being defined in other agreements shall have the meanings set forth in the Credit Agreement, the Lenders have agreed to make certain extensions of credit to the Borrower under the Credit Agreement, all as more specifically described therein;

WHEREAS, it is a condition precedent to the obligation of the Lenders to make their respective extensions of credit to the Borrower under the Credit Agreement that the Grantors execute and deliver this Intellectual Property Security Agreement to the Administrative Agent for recording with the United States Patent and Trademark Office and the United States Copyright Office; and

WHEREAS, the Grantors desire to execute this Intellectual Property Security Agreement to satisfy the condition described in the preceding paragraph.

### AGREEMENT

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantors agree as follows:

SECTION 1. GRANT OF SECURITY. The Grantors hereby grant to the Administrative Agent, for the ratable benefit of the Lenders, a security interest in and to all of Grantors’ right, title and interest in and to the following (the “Intellectual Property Collateral”), as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Grantors’ Obligations (as defined in the Guarantee and Collateral Agreement):

(a) (1) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith (other than any “intent to use” trademark application for which a statement of use has not yet been filed (but only until such statement is filed with, and accepted by, the United States Patent and Trademark Office or the equivalent thereof in any jurisdiction)), including, without limitation, each trademark registration and application for trademark registration identified in Schedule 1, (2) the right to obtain all renewals thereof, (3) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations thereof, (4) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof), and (5) all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto, together in each case with the goodwill of the business connected with the use of, and symbolized by, each of the above (collectively, the “Trademarks”);

(b) (1) all letters patent, all reissues and extensions thereof, including, without limitation, any of the foregoing identified in Schedule 2, (2) all applications for letters patent and all divisions, continuations and continuations-in-part thereof, including, without limitation, any of the foregoing identified in Schedule 2, (3) all rights to obtain any reissues or extensions of the foregoing, (4) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations thereof, and (5) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof) (collectively, the “Patents”);

(c) (1) all copyrights, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof, and all applications in connection therewith, including, without limitation, all copyright registrations, and applications for copyright registrations identified in Schedule 3, (2) the right to obtain all renewals thereof, (3) the rights to print, publish and distribute any of the foregoing, (4) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations thereof, (5) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof), and (6) all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto (collectively, the “Copyrights”);

(d) (1) all Patent Licenses, Trademark Licenses, and Copyright Licenses, as defined in the Guarantee and Collateral Agreement (except to the extent any such Patent License, Trademark License or Copyright License constitutes Excluded Intellectual Property, as defined in the Guarantee and Collateral Agreement) (2) the right to sue or otherwise recover for any and all past, present and future infringements or misappropriations of any of the foregoing, (3) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements

thereof), and (4) all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto;

(e) all of Grantor's right, title and interest in and to the Security Interest (defined below) pursuant to that certain Amended and Restated Intellectual Property Security Agreement dated December 1, 2017, whereby CMP Development LLC ("CMP Development") has granted to Grantor a continuing security interest in certain Intellectual Property Collateral (as defined therein), including, without limitation, the CAROSPIR trademark identified on Schedule 1 and the patents identified on Schedule 2 (the "Security Interest"); and

(f) any and all proceeds of the foregoing.

SECTION 2. RECORDATION. The Grantors authorize and request that the Register of Copyrights, the Commissioner of Patents and Trademarks and any other applicable government officer record this Intellectual Property Security Agreement.

SECTION 3. EXECUTION IN COUNTERPARTS. This Intellectual Property Security Agreement may be executed in any number of counterparts (including by telecopy), each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.


SECTION 4. GOVERNING LAW. Unless otherwise expressly set forth herein, this Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York (including Sections 5-1401 and 5-1402 of the General Obligations Law of the State of New York) without reference to the conflicts or choice of law principles thereof other than such Section 5-1401, except to the extent that the laws of a particular jurisdiction other than the State of New York govern the perfection, priority or enforcement of liens on and security interests in the Collateral.

SECTION 5. CONFLICT PROVISION. This Intellectual Property Security Agreement has been entered into in conjunction with the provisions of the Credit Agreement and the Guarantee and Collateral Agreement. The rights and remedies of each party hereto with respect to the security interest granted herein are without prejudice to, and are in addition to those set forth in the Guarantee and Collateral Agreement and the Credit Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Intellectual Property Security Agreement are in conflict with the Guarantee and Collateral Agreement or the Credit Agreement, the provisions of the Guarantee and Collateral Agreement or the Credit Agreement shall govern.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the undersigned Grantors have caused this Intellectual Property Security Agreement to be duly executed and delivered as of the date first above written.

CMP PHARMA, INC.

By:  \_\_\_\_\_

Name: Gerald Sakowski

Title: Chief Executive Officer

CMP ACQUISITION COMPANY LLC

By: \_\_\_\_\_

Name: George Aitken-Davies


Title: President and Secretary

IN WITNESS WHEREOF, the undersigned Grantors have caused this Intellectual Property Security Agreement to be duly executed and delivered as of the date first above written.

CMP PHARMA, INC.



By: \_\_\_\_\_  
Name: Gerald Sakowski  
Title: Chief Executive Officer

CMP ACQUISITION COMPANY LLC

By:  \_\_\_\_\_  
Name: George Aitken-Davies  
Title: President and Secretary

**Schedule 1 to Intellectual Property Security Agreement**

**REGISTERED TRADEMARKS AND TRADEMARK APPLICATIONS**

<b>Owner</b>	<b>Mark</b>	<b>Jurisdiction</b>	<b>Serial No. / Registration No.</b>	<b>Application/ Registration Date</b>
CMP Pharma, Inc.	CAROLINA MEDICAL PRODUCTS CO.	US	4,031,253	9/27/11
CMP Pharma, Inc.	CMP (design) 	US	1,526,453	2/28/89
CMP Pharma, Inc.	DERMACLOUD	US	4,028,443	9/20/11
CMP Pharma, Inc.	SPS	US	1,288,620	8/7/84
CMP Pharma, Inc.	ABSORBASE	North Carolina	010568	6/2/93
CMP Pharma, Inc.	CAROLINA MEDICAL PRODUCTS CO.	US	3,358,469	12/25/07
CMP Pharma, Inc.	ABSORBASE	US	1,600,274	6/12/90
CMP Pharma, Inc.	ORACIT	US	1,377,857	1/14/86
CMP Pharma, Inc.	  for pharmaceutical preparations for skin care; pharmaceutical ointment bases in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; systemic alkalinizing agents for use as pharmaceutical preparations to assist in	US	4,517,401	4/22/14



<b>Owner</b>	<b>Mark</b>	<b>Jurisdiction</b>	<b>Serial No. / Registration No.</b>	<b>Application/ Registration Date</b>
	the maintenance of healthy pH balance; topical steroid preparations; pharmaceutical preparations for the treatment of kidney disorders, hyperkalemia, gastric distress, diseases of the respiratory system, and constipation			
CMP Pharma, Inc.	TRIANEX for pharmaceutical products, namely, topical corticosteroids	US	4,046,667	10/25/11

Amended and Restated Intellectual Property Security Agreement dated December 1, 2017, whereby CMP Development LLC granted a security interest in favor of CMP Pharma, Inc. covering the following trademark:

<b>Owner</b>	<b>Mark</b>	<b>Jurisdiction</b>	<b>Serial No. / Registration No.</b>	<b>Application/ Registration Date</b>
CMP Development LLC	CAROSPIR for pharmaceutical preparations for the treatment of primary hyperaldosteronism, edema, hypertension, hypokalemia, severe heart failure, hormonal disorders	US	86418628	10/8/14

**Schedule 2 to Intellectual Property Security Agreement**

**REGISTERED PATENTS AND PATENT APPLICATIONS**

Amended and Restated Intellectual Property Security Agreement dated December 1, 2017, whereby CMP Development LLC granted a security interest in favor of CMP Pharma, Inc. covering the following patents:

<b>Patent Title</b>	<b>Patent Application Number</b>	<b>Patent Number</b>	<b>Filing Date</b>	<b>Issue Date</b>
Spironolactone aqueous formulations	15/337,559	9757394	10/28/16	9/12/17
Spironolactone Aqueous Compositions	15/665,014		7/31/17	
Spironolactone Aqueous Compositions	PCT/US2016/59483		10/28/16	

**Schedule 3 to Intellectual Property Security Agreement**

**REGISTERED COPYRIGHTS AND COPYRIGHT APPLICATIONS**

<b>Full Title</b>	<b>Copyright Number</b>	<b>Date</b>
<i>"Isoniazid syrup USP"</i>	TX0002138317	8/3/87
<i>"Oracit"</i>	TX0002138363	8/3/87
<i>"SPS suspension"</i>	TX0001687393	2/27/85

23824264.5